GSK plc’s Jemperli has received a US Food and Drug Administration green light for use with chemotherapy in mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) first-line endometrial cancer earlier than expected, but competition from Merck & Co., Inc. is on the horizon.
GSK's Jemperli First-Line Endometrial Cancer Approval Fillip Ahead Of Keytruda Advance
With Restricted Label
The major’s PD-L1 inhibitor is the first to win US approval for the treatment of first-line endometrial cancer in combination with chemotherapy, but an unsurprisingly narrow label means rival Merck & Co.’s Keytruda could still make a splash in this indication.
More from New Products
More from Scrip
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.